A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 1232-1240

  Reynolds, Craig ^a,b   Di Bella, Nicholas ^a,c   Lyons, Roger M ^a,d   Hyman, William ^a,e   Richards, Donald A ^a,e   Robbins, Gerald J ^a,f   Vellek, Mark ^a,g   Boehm, Kristi A ^a   Zhan, Feng ^a   Asmar, Lina ^a  

^a US Oncology Research   (United States)

^b Ocala Oncology   (United States)

^c ROCKY MOUNTAIN CANCER CENTERS   (United States)

^d Cancer Care Centers of South Texas   (United States)

^e TEXAS ONCOLOGY   (United States)

^f Florida Cancer Institute   (United States)

^g Missouri Cancer Associates   (United States)

Author keywords

Chemotherapy; Community based; Comparative; Infection; Leukemia

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; PENTOSTATIN; RITUXIMAB;

ADULT; ADVERSE OUTCOME; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CONFUSION; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; INFECTION RATE; KIDNEY FAILURE; LENGTH OF STAY; LEUKOCYTOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYASTHENIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PENTOSTATIN; TREATMENT OUTCOME; VIDARABINE;

EID: 84864336293     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9737-y     Document Type: Article

References (17)

1. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J et al (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9(1):44-49
2. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343(24):1750-1757
3. Rai KR, Peterson BL, Appelbaum FR, Tallman MS, Belch A, Morrison VA, et al (2000) Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114:536
4. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19(8):2165-2170 (Pubitemid 32366970)
5. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R et al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98(5):1326-1331
6. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE et al (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis ofCALGB 9712 and CALGB 9011. Blood 105(1):49-53 (Pubitemid 40053062)
7. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al (2005) Chemoimmunotherapy with fludar-abine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (18):4070-4078 (Pubitemid 46211312)
8. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088 (Pubitemid 46211313)
9. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-980
10. Dillman RO, Mick R, McIntyre OR (1998) Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 7(4):433-438
11. Ho AD, Thaler J, Stryckmans P, Coiffier B, Luciani M, Sonneveld P et al (1990) Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment ofCancer. Natl Cancer Inst 82(17):1416-1420 (Pubitemid 20261056)
12. Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N et al (2003) Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21(7):1278-1284 (Pubitemid 46606404)
13. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF et al (2007) Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows signifi-cant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109(2):405-411 (Pubitemid 46105933)
14. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B et al (2007) Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109 (11):2291-2298 (Pubitemid 46801560)
15. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al (1996) National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 12:4990-4997 (Pubitemid 26189840)
16. National Cancer Institute's Cancer Therapy Evaluation Pro-gram (NCI CTEP) Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0. URL: http://ctep.cancer. gov/protocolDevelopment/electronic-applications/docs/ ctcaev3. pdf(accessed August 8, 2009)
17. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. JASA 53:457-481